Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats

Author(s):  Eichstadt Lauren R, Corriveau Lorraine A, Moore George E, Knipp Gregory T, Cooper Bruce R, Gwin Wilson E

Issue:  May/Jun 2017 - Volume 21, Number 3
View All Articles in Issue

Page(s):  242-246

Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 1
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 2
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 3
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 4
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 5

Download in electronic PDF format for $75

Abstract:  The objective of this study was to compare serum concentrations of transdermal fluoxetine compounded in Lipoderm base versus commercially available oral fluoxetine tablets. Sixteen clinically healthy, client-owned cats that were at least one year of age were enrolled. Cats weighed between three and seven kilograms, had no comorbidities, and were behavior medication naïve. Cats were recruited from January 2016 through April 2016. Eight cats were assigned to each medication group based on owner preference. The cats received either oral (1 mg/kg) or transdermal (5 mg/kg; maximum 25 mg daily) fluoxetine compounded in a transdermal base (PCCA Lipoderm), administered daily for 60 days. Serum levels of fluoxetine and norfluoxetine were assessed as a surrogate for relative efficacy. Serum was collected and analyzed by high-performance liquid chromatography-mass spectrometry/mass spectrometry at baseline and days 5, 10, 30, 45, and 60 post-drug start. Adverse effects were monitored during physical exams, speaking with owners, and laboratory analysis of liver function tests at baseline and days 5, 30, and 60 post-drug start. Serum fluoxetine concentrations significantly differed between the treatment groups at days 45 and 60 post-drug start. Norfluoxetine concentrations significantly differed at days 30, 45, and 60 post-drug start. Blood concentrations of fluoxetine and norfluoxetine significantly differed between oral and transdermal routes after 30 days of treatment. Oral fluoxetine concentrations were consistently higher. Transdermal fluoxetine appeared to be well-tolerated, but a lack of knowledge regarding effective blood levels makes it unclear if a clinical effective response would be obtained at the blood concentrations achieved.

Related Keywords: Lauren R. Eichstadt, PharmD, Lorraine A. Corriveau, DVM, George E. Moore, DVM, PhD, Gregory T. Knipp, PhD, Bruce R. Cooper, PhD, Wilson E. Gwin, RPh, fluoxetine, selective serotonin reuptake inhibitor, SSRI, felines, anxiety, behavioral disorders, obsessive compulsive disorder, OCD, topical preparation, transdermal administration, transdermal absorption, serum drug concentrations, oral preparation, dosage form comparison

Related Categories: PEER-REVIEWED, VETERINARY, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats
Eichstadt Lauren R
, Corriveau Lorraine A, Moore George E, Knipp Gregory T, Cooper Bruce R, Gwin Wilson E
May/Jun 2017
Pg. 242-246

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B
, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2020
Pg. 327-336

Case Report: Transdermal Fluoxetine as Therapy for Feline Anxiety
Fields Shannon W
Nov/Dec 2006
Pg. 418

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Fluoxetine 50 mg/mL in Pluronic Lecithin Organogel
Allen Loyd V Jr
Sep/Oct 2018
Pg. 409

Drug Therapy for Acute and Chronic Pain in the Cat
Lascelles B Duncan
Sep/Oct 2002
Pg. 338-343

Fluoxetine Hydrochloride 1-mg/mL Oral Liquid
Allen Loyd V Jr
Jan/Feb 2007
Pg. 73

Transdermal Amlodipine Besylate in Lipoderm for the Treatment of Feline Hypertension: A Report of Two Cases
Mixon William
, Helms Scott R
Sep/Oct 2008
Pg. 392-397

Case Studies of Compounded Tramadol Use in Cats
Ray Joel
, Jordan Dinah, Pinelli Chris, Fackler Bethany, Boggess Donan, Clark Justin
Jan/Feb 2012
Pg. 44-49

Compounding and the Specialty Veterinary Practice: An Interview with Gary Riggs, DVM, ABVP
Allen Loyd V Jr
May/Jun 1999
Pg. 172-175

A Review of Stomatitis and Treatment in Cats
Ray Jody D
, Jordan Dinah G, Eubanks Diana L, Crosswhite Megan E
Sep/Oct 2009
Pg. 372-381

Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F
, Sauvageot Jurgita
May/Jun 2014
Pg. 253-255

To Compound or Not to Compound: A Veterinary Transdermal Discussion
Eichstadt Lauren R
, Davidson Gigi S
Sep/Oct 2014
Pg. 366-369

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Calculations
Prince Shelly J
Sep/Oct 2002
Pg. 387

Feline Transdermal Formulation Considerations
Forsythe Lauren Eichstadt
Nov/Dec 2017
Pg. 446-452

Conservative Management of Chronic Kidney Disease in Cats: Recommendations for Veterinarians and Compounding Pharmacists
Meadows Richard L
, Muller George
Sep/Oct 2010
Pg. 382-394

Compounding Transdermal Medication for Feline Patients
Eichstadt Lauren R
Jul/Aug 2016
Pg. 271-274

Return to Top